Gilead Reports Phase 3 Data for Reslizumab in Melanoma

Gilead today announced Phase 3 results for reslizumab in patients with melanoma. The study demonstrated that reslizumab achieves complete response compared to standard of care or placebo. These results provide important insights into the treatment of melanoma and support the continued development of reslizumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.